secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyra Therapeutics, Inc. (LYRA)
CIK:        0001327273
Form:       8-K
Filed at:   2023-03-29T23:59:59+00:00
Accession:  0000950170-23-010621
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyra Therapeutics reports FY2022 net loss $55.3M; cash $97.9M; ENLIGHTEN I on track for mid-2023 enrollment completion
--------------------------------------------------------------------------------

- Net loss for FY2022 $55.3M vs $43.5M in 2021; Q4 net loss $14.2M.
- Cash and investments $97.9M as of Dec 31, 2022; sufficient into mid-2024.
- ENLIGHTEN I Phase 3 enrollment completion on track for mid-2023; ENLIGHTEN II resume enrollment Q2 2023 (ahead of prior Q3 2023).
- BEACON Phase 2 data for LYR-220 expected Q4 2023.
- Transitioned manufacturing in-house to prepare for commercial production.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1327273/000095017023010621/0000950170-23-010621-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1327273/000095017023010621/lyra-20230329.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-010621

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer